A single CRISPR infusion lowers LDL cholesterol by half in a Phase 1 trial
Cleveland Clinic investigators report CTX310 cut LDL roughly 50 percent and triglycerides 55 percent after one dose, pushing in vivo editing toward common disease rather than rare disease.
The trial was small. The framing is not. For most of the last decade, in vivo CRISPR has been a rare-disease proposition — bespoke therapies priced at millions of dollars for patient populations measured in the thousands. CTX310 is the first credible attempt at the opposite case: a lipid-nanoparticle-delivered one-time edit, aimed at a gene the general population carries, for a condition the general population has.
CRISPR Therapeutics' Phase 1 readout, reported at the American College of Cardiology's late-breaking sessions in November 2025, is the quiet pivot. Investigators at Cleveland Clinic dosed patients with refractory hypercholesterolemia and severe hypertriglyceridemia using a single intravenous infusion targeting ANGPTL3, a gene loss-of-function carriers tolerate without apparent harm. Reductions in LDL-C approached fifty percent at the higher dose cohort. Triglycerides fell by roughly fifty-five percent. No serious adverse events attributable to the therapy were reported at the interim cut-off.
The mechanism is what makes the number interesting. Unlike the ex vivo edits behind Casgevy, CTX310 is administered as an infusion and edits the gene in the liver directly — no cell extraction, no conditioning regimen, no transplant ward. The unit economics at scale are closer to a biologic than to a cell therapy, which is the economic threshold the category has been waiting for. CRISPR Therapeutics has now advanced the program into Phase 1b in both indications, with a pair of Phase 2 starts guided for 2026.
The winners are Verve, Eli Lilly, and every programme already modelling one-shot cardiometabolic edits as the second wave of gene therapy. The losers are the statin and PCSK9 franchises whose decade-long contract with cardiovascular prescribing now contends with an intervention that is, in principle, a single outpatient visit. Insurers will take longer than clinicians to work out what that transition looks like on a payer's ledger.
What a successful Phase 2 forecloses is the idea that CRISPR must remain a boutique tool for orphan indications. What it opens is harder: a regulatory framework for treating a chronic condition with a permanent edit. The FDA has not previously approved a drug whose duration of action is, effectively, the rest of a patient's life. It will have to.